We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK’s RSV Vaccine Highly Effective Against Severe Disease in Older Adults, Data Show
GSK’s RSV Vaccine Highly Effective Against Severe Disease in Older Adults, Data Show
GSK has unveiled impressive numbers for its respiratory syncytial virus (RSV) vaccine, touting an overall efficacy rate of more than 94 percent against severe disease in people age 60 years and older.